Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.

Cancer research - 15 Nov 2012

Serra Stefano, Zheng Lei, Hassan Manal, Phan Alexandria T, Woodhouse Linda J, Yao James C, Ezzat Shereen, Asa Sylvia L

Abstract excerpt

Pancreatic neuroendocrine tumors (pNET), also known as islet cell tumors, exhibit a wide range of biologic behaviors ranging from long dormancy to rapid progression. Currently, there are few molecular biomarkers that can be used to predict recurrence/metastasis or response to therapy. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Neuroendocrine
Share to Cell Growth Processes
Share to Everolimus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, SCID

Share to Receptor, Fibroblast Growth Factor, Type 4

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 22986737
DOI: 10.1158/0008-5472.CAN-12-2102

Genes

FGFR4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22986737-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy.PMID 22986737Read ↗

Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.Semantic proximity Read ↗

The cancer-associated FGFR4-G388R polymorphism enhances pancreatic insulin secretion and modifies the risk of diabetes.Semantic proximity Read ↗

Dysregulation of CELF4 splicing factor in pancreatic neuroendocrine tumors enhances aggressiveness and alters mTOR pathway and everolimus responseSemantic proximity Read ↗

FGFR4 Gly388Arg Polymorphism Affects the Progression of Gastric Cancer by Activating STAT3 Pathway to Induce Epithelial to Mesenchymal Transition.Semantic proximity Read ↗

Analysis of polymorphisms in EGF, EGFR and HER2 genes in pancreatic neuroendocrine tumors (PNETs).Semantic proximity Read ↗

Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.Semantic proximity Read ↗

A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.Semantic proximity Read ↗

RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition.Semantic proximity Read ↗

The FGFR4-G388R polymorphism promotes mitochondrial STAT3 serine phosphorylation to facilitate pituitary growth hormone cell tumorigenesis.Semantic proximity Read ↗

The role of pharmacogenomics in metastatic renal cell carcinoma.Semantic proximity Read ↗

CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.Semantic proximity Read ↗

Elevated Serum Amino Acids Induce a Subpopulation of Alpha Cells to Initiate Pancreatic Neuroendocrine Tumor FormationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.